Advert Shionogi Europe

• Date posted
  01 February 2021
• Sanction
  Advertisement,
• Case number/s
  AUTH/3343/5/20 - Complainant v Shionogi Europe

For promoting Fetcroja (cefiderocol), both before and after it received its marketing authorization, on LinkedIn, Shionogi Europe was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.

Clause 3.1 - Promoting an unlicensed medicine

Clause 9.1 - Failing to maintain high standards

Clause 26.1 - Promoting a prescription only medicine to the public

Clause 26.2 - Encouraging members of the public to ask for a specific prescription only medicine